BE&K has dedicated over two years of detailed preparation for a new multi-product facility adjacent to Novo Nordisk’s existing operations in Clayton, NC, providing estimates, schedules, and procurement strategies and has begun construction. The ambitious project will involve the construction of ten or more buildings and multi-building combinations, providing more than 1.4 million square feet.
BE&K will directly perform a significant portion of the work as Construction Manager and will serve as the Agency Construction Manager for the remainder of the work, providing oversight for the development of the facility that will span approximately 56 acres. The final state-of-the-art facility will be instrumental in manufacturing Novo Nordisk’s innovative treatments for obesity and other chronic diseases. Construction will gradually be finalized between 2027 and 2029.
Clayton was the first manufacturing site for Novo Nordisk in the US, and this new, large-scale investment here confirms the continued importance of our production facilities in North Carolina. We are proud to be one of the cornerstones of our company’s growth. For decades, we’ve partnered to foster a well-trained, dedicated and diverse local workforce here. We are one team driven by one purpose: to deliver more for the millions of people living with chronic diseases – and we will achieve that with this facility.
— Niels Laurbjerg Nielsen, Corporate Vice President, Novo Nordisk